Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2010
Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00106288 (A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.Haematologica · 2017Guideline
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.BMC infectious diseases · 2013Trial
- Epidemiology, Species Susceptibility, and Mortality Risk Factors of Pediatric Candidemia: A 13-Year Multicenter Study.Journal of fungi (Basel, Switzerland) · 2026Article
- Role of source control in critically ill candidemic patients: a multicenter retrospective study.Infection · 2024Article
- Comparative Analysis of Capsular and Secreted Polysaccharides Produced byJournal of fungi (Basel, Switzerland) · 2023Article
- DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.Advanced drug delivery reviews · 2023Review
- Molecular Investigation of the Fatal BloodstreamInternational journal of molecular sciences · 2023Article
- Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors.Journal of fungi (Basel, Switzerland) · 2023Article
- Κey Role of Early Source Control in Candidemic Patients With Sepsis or Septic Shock.Open forum infectious diseases · 2022Article
- DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.Antimicrobial agents and chemotherapy · 2022Article
- Natural Variation in Clinical Isolates of Candida albicans Modulates Neutrophil Responses.mSphere · 2020Article
- Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Antimicrobial stewardship without infectious disease physician for patients with candidemia: A before and after study.Journal of general and family medicine · 2018Article
- Fungal Recognition and Host Defense Mechanisms.Microbiology spectrum · 2017Review
- Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.Intensive care medicine · 2017Article
- The environmental yeast Cryptococcus liquefaciens produces capsular and secreted polysaccharides with similar pathogenic properties to those of C. neoformans.Scientific reports · 2017Article
- "De-escalation" strategy using micafungin for the treatment of systemicClinicoEconomics and outcomes research : CEOR · 2017Article
- Autophagy and Reactive Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. albicans Morphotypes.Frontiers in microbiology · 2016Article
- Assessing responses to treatment of opportunistic mycoses and salvage strategies.Current infectious disease reports · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crude and attributable mortality rates in patients with candidemia and invasive candidiasis remain unacceptably high. It is important to reach a more complete understanding of the risk factors underlying poor outcomes in patients with invasive Candida infections. Micafungin therapy has been assessed in two phase 3 trials compared to either liposomal amphotericin B or caspofungin. The availability of this large dataset allows the analyses of non-drug factors associated with survival and treatment success. A multivariate regression analysis was performed on data from the two trials separately and as a pooled analysis (N = 1,070). Analysis outcomes were survival at 42 days post-initiation of therapy and treatment success. For the pooled analysis, treatment success was significantly more likely for candidemia than invasive candidiasis. Both survival and treatment success were significantly less likely for the non-removal of catheter versus removal, Asian-Indians versus Caucasians, APACHE II score >20 to <or=30 and >30 versus <or=20, age >or=70 years versus <50 years, baseline corticosteroids, and persistent neutropenia. Survival was also significantly less likely for treatment in other regions versus North America and for patients with renal failure at baseline. These findings help to define non-antifungal drug factors that may impact survival and treatment success in invasive candidiasis or candidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.